Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.

Bank of America Securities analyst Graham Parry maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) yesterday and set a ...

GSK plc GSK announced positive topline results from a phase III study evaluating the co-administration of its two marketed ...

(Reuters) - The latest trial over claims that the discontinued heartburn drug Zantac causes cancer ended with a hung jury on ...

British drugmaker GSK said on Wednesday it had agreed to settle two lawsuits in California that claimed its discontinued ...

J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of ...